title: Epidemiological, clinical, and therapeutic aspects of primary intracerebral hemorrhage.
abstract: Primary intracerebral hemorrhage is the least treatable form of stroke and is associated with high mortality rates. In the thrombolytic era, the attention has bee driven on the first hours of onset, when the hematoma is still growing. Intervention with ultra-early hemostatic therapy might arrest ongoing bleeding. Even if recombinant activated factor VII administered within 4 h of symptom onset did not improve outcome in a recent phase 3 trial, it reduced hematoma growth. Therefore, the rational for ultra-early hemostatic therapy it is still valid and another trial on hemostatic treatment is warranted.
authors.affiliation: Stroke Unit, Department of Neurosciences, Niguarda Ca' Granda Hospital, Milan, Italy. Alfonso.Ciccone@ospedaleniguarda.it
authors.forename: Alfonso
authors.initials: A
authors.lastname: Ciccone
authors.forename: Mario
authors.initials: M
authors.lastname: Pozzi
authors.forename: Cristina
authors.initials: C
authors.lastname: Motto
authors.forename: Pietro
authors.initials: P
authors.lastname: Tiraboschi
authors.forename: Roberto
authors.initials: R
authors.lastname: Sterzi
mesh_terms: D000933:Antifibrinolytic Agents / Q000008:administration & dosage; D002536:Cerebral Arteries / Q000187:drug effects* / Q000473:pathology / Q000503:physiopathology; D002543:Cerebral Hemorrhage / Q000188:drug therapy* / Q000453:epidemiology / Q000503:physiopathology; D003029:Coagulants / Q000008:administration & dosage* / Q000009:adverse effects; D004334:Drug Administration Schedule; D042241:Early Diagnosis; D015942:Factor VIIa / Q000008:administration & dosage* / Q000009:adverse effects; D006801:Humans; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000009:adverse effects; D013997:Time Factors; D014148:Tranexamic Acid / Q000008:administration & dosage
chemical_list: D000933:Antifibrinolytic Agents; D003029:Coagulants; D011994:Recombinant Proteins; D014148:Tranexamic Acid; D015942:Factor VIIa